Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | MPI | P34949 | 1/20 | 0.31 |
| ▸ | CA4 | P22748 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27337469 | 1.00 | — | — | |
| SCHEMBL875835 | 1.00 | — | — | |
| Water SCHEMBL28524171 | 0.97 | FDPS (0.37) | FDPSBLMTDP1MPI | |
| SCHEMBL1332890 | 0.97 | — | — | |
| SCHEMBL29020521 | 0.93 | — | — | |
| SCHEMBL6905808 | 0.93 | — | — | |
| Ammonia Solution, Strong SCHEMBL27782827 | 0.93 | — | — | |
| SCHEMBL2403749 | 0.93 | — | — | |
| SCHEMBL22720208 | 0.93 | — | — | |
| Formic Acid SCHEMBL20854282 | 0.90 | FDPS (0.37) | FDPSBLMTDP1MPI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 349 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119948053-A | Anti-SARS-CoV-2 antigen binding polypeptides, polypeptide complexes, and methods of use thereof | 摩德斯医疗股份有限公司 | 2025-05-06 | — | — | CN | claimed |
| EP-3808743-B1 | HIV REPLICATION INHIBITING PYRIMIDINES | JANSSEN PHARMACEUTICA NV (BE) | 2022-07-20 | — | — | EP | claimed |
| EP-3808743-A1 | HIV REPLICATION INHIBITING PYRIMIDINES | Janssen Pharmaceutica NV (BE) | 2021-04-21 | — | — | EP | claimed |
| EP-3230455-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) INFECTIONS | Institut National de la Santé et de la Recherche Médicale (INSERM) (FR) | 2017-10-18 | — | — | EP | claimed |
| WO-2016092041-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) INFECTIONS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2016-06-16 | — | — | WO | claimed |
| US-7037917-B2 | HIV replication inhibiting pyrimidines | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-05-02 | — | — | US | claimed |
| US-20040039005-A1 | Nitrogen compounds such as 4-((4-amino-5-bromo-6-(4-cyano-2,6-dimethylphenyloxy)-2 -pyrimidinyl)amino)benzonitrile, used as protease inhibitors for prophylaxis of viral diseases | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-02-26 | — | — | US | claimed |
| US-20030199473-A1 | Substituted diamino-1,3,5-triazine derivatives | JANSSEN PHARMACEUTICA N.V. | 2003-10-23 | — | — | US | claimed |
| EP-3528791-B1 | DISPERSIBLE COMPOSITIONS | JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) | 2023-12-06 | — | — | EP | disclosed |
| EP-4248947-A2 | DISPERSIBLE COMPOSITIONS | Janssen Sciences Ireland Unlimited Company (IE) | 2023-09-27 | — | — | EP | disclosed |
| EP-1663240-B2 | COMBINATIONS OF A PYRIMIDINE CONTAINING NNRTI WITH RT INHIBITORS | JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) | 2023-03-01 | — | — | EP | disclosed |
| EP-3808743-B1 | HIV REPLICATION INHIBITING PYRIMIDINES | JANSSEN PHARMACEUTICA NV (BE) | 2022-07-20 | — | — | EP | disclosed |
| EP-1632232-B3 | Salt of 4[[4-[[4-(2-Cyanoethenyl)-2,6-dimethylphenyl]amino]-2-Pyrimidinyl]amino]benzonitrile | JANSSEN PHARMACEUTICA NV (BE) | 2022-03-30 | — | — | EP | disclosed |
| US-20220008417-A1 | COMBINATIONS OF A PYRIMIDINE CONTAINING NNRTI WITH RT INHIBITORS | Janssen Sciences Ireland Unlimited Company (IE) | 2022-01-13 | — | — | US | disclosed |
| WO-1999050250-A1 | HIV INHIBITING PYRIMIDINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1999-10-07 | — | — | WO | disclosed |
| EP-0945442-A1 | Trisubstituted pyrimidine derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 1999-09-29 | — | — | EP | disclosed |
| EP-0945443-A1 | HIV inhibiting pyrimidine derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 1999-09-29 | — | — | EP | disclosed |
| EP-0945447-A1 | Trisubstituted 1,3,5-triazine derivatives for treatment of HIV infections | JANSSEN PHARMACEUTICA N.V. (BE) | 1999-09-29 | — | — | EP | disclosed |
| WO-1999045025-A1 | ACYLATED BETULIN AND DIHYDROBETULIN DERIVATIVES, PREPARATION THEREOF AND USE THEREOF | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 1999-09-10 | — | — | WO | disclosed |
| EP-0834507-A1 | Substituted diamino-1,3,5-triazine derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 1998-04-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199473-A1 | Substituted diamino-1,3,5-triazine derivatives | CCR1, CCR6, CCR5 | FDPS 2146/4885BLM 4118/4885TDP1 2017/4885 |
| US-20040039005-A1 | Nitrogen compounds such as 4-((4-amino-5-bromo-6-(4-cyano-2,6-dimethylphenyloxy)-2 -pyrimidinyl)amino)benzonitrile, used as protease inhibitors for prophylaxis of viral diseases | CPN1, CTRL, HPN | FDPS 4184/4885BLM 1342/4885TDP1 828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.